In the world of investing, sometimes a dip can signal a hidden opportunity. IMAC Holdings has recently seen its stock drop over 3%, even as the broader market rallies. With a market cap of $3M and total revenue of $5.2M, the company operates in the healthcare sector, specifically in health care equipment and supplies. Despite facing challenges, including a net income loss of 14.9M, the current ratio of 1.18X suggests it can cover its short-term liabilities. The stock's price-to-sales ratio of 0.59X indicates it may be undervalued compared to its revenue. With a target price of $8.25, investors might find this pullback an intriguing entry point, especially considering the low short interest of 0.0103. Novo Integrated is likely to bounce back more quickly from its recent decline, with its stock rising by 2.63%, compared to IMAC Holdings, which increased by 3.87%. As many baby boomers remain uninterested in the healthcare equipment and supplies sector, we will focus on both IMAC Holdings and Novo Integrated Sciences. Our analysis will delve into the competitive dynamics of these two companies, exploring their strengths and weaknesses in the market.
Investment perspective, in general, refers to a viewpoint or opinion regarding investment opportunity in IMAC Holdings. It encompasses the assessment of an investment's potential risks and rewards, and expectations for its
performance over time. Several factors influence the investment perspective on IMAC Holdings, including investment goals, risk tolerance, time horizon, market conditions, and research and analysis. Investors have varying goals, such as capital preservation, income generation, or long-term growth. Risk tolerance plays a significant role in shaping an investor's perspective, with some being more risk-averse and others willing to take on higher risks for potential returns.
Watch out for price decline
Please consider monitoring IMAC Holdings on a daily basis if you are holding a position in it. IMAC Holdings is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as IMAC Holdings stock to be traded above the $1 level to remain listed. If IMAC Holdings stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is IMAC Holdings's Liquidity
IMAC Holdings
financial leverage refers to using borrowed capital as a funding source to finance IMAC Holdings ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. IMAC Holdings financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to IMAC Holdings' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of IMAC Holdings' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between IMAC Holdings's total debt and its cash.
IMAC Holdings Gross Profit
IMAC Holdings Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing IMAC Holdings previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show IMAC Holdings Gross Profit growth over the last 10 years. Please check IMAC Holdings'
gross profit and other
fundamental indicators for more details.
Is IMAC Holdings valued adequately by the market?
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Revenue Breakdown
Let me take a closer look at IMAC Holdings revenue. Based on the latest financial disclosure, IMAC Holdings reported 5.2
M of revenue.
This is 99.93% lower than that of the Health Care Equipment & Supplies sector and significantly higher than that of the
Health Care industry. The revenue for all United States stocks is 99.94% higher than that of IMAC Holdings. As for Novo Integrated we see revenue of 11.74
M, which is much higher than that of the Health Care
| IMAC | 5.2 Million |
| Sector | 0.0 |
| Novo | 11.74 Million |
In the world of investing, sometimes the best opportunities arise when others are fearful. IMAC Holdings (USA: BACK) has seen its stock dip over 3% even as the broader market rallies, raising questions about whether this presents a buying opportunity. With a current price around 1.78, significantly lower than its 52-week high of 7.75, the stock appears undervalued, especially considering its potential upside of 10.69%. However, the company faces challenges, including losses of 6.5 million and a concerning probability of bankruptcy at 96%. Investors should weigh these risks against the potential for recovery, particularly in the healthcare sector where IMAC operates..
Will IMAC Holdings latest slide continue?
IMAC Holdings has recently experienced a drop in its total risk alpha indicator to -1.11, raising concerns about the sustainability of its current decline. This downturn might indicate that the stock is undervalued, potentially paving the way for a rebound as investors look for opportunities in a recovering market. However, uncertainty looms over whether this positive momentum will develop or if the downward trend will continue, leaving investors anxious about the company's future.
The stock is showing above-average volatility, which can help investors time their moves. Understanding market volatility trends is crucial, as the heightened fluctuations during bear markets can significantly affect IMAC Holdings' stock price.
This situation often prompts investors to adjust their portfolios, seeking stability as prices fall.Despite a general market upswing, IMAC Holdings has seen its stock price dip by over 3%. This decline raises eyebrows, especially when considering the analyst consensus, which leans heavily towards a "Strong Buy." With an estimated target price ranging from
31.4 to
38.3, the potential for recovery seems promising. Investors should weigh the current valuation, which stands at a mere
1.74, against the projected upside of
8.16. As the fiscal year wraps up in December, this could be an opportune moment for savvy investors to consider adding IMAC to their portfolios, especially if they believe in the company's long-term growth potential..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of IMAC Holdings. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]